0.9951

0.49% -0.0049

After Hours: 1.00 0.0049 +0.49%

Jaguar Health Inc (JAGX)

Overview News Price History Financials Why JAGX Down? Discussions Forecast Stock Split

Jaguar Health Inc stock is traded at $0.9951, with a volume of 117.20K. It is down -0.49% in the last 24 hours and down -10.35% over the past month. Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Previous Close:

$1.00

Open:

$1.04

24h Volume:

117.20K

Relative Volume:

0.46

Market Cap:

$11.45M

Revenue:

$10.72M

Net Income/Loss:

$-39.71M

P/E Ratio:

-0.064

EPS:

-15.5542

Net Cash Flow:

$-32.21M

1W Performance:

+1.55%

1M Performance:

-10.35%

6M Performance:

-78.51%

1Y Performance:

-95.26%

1-Day Range:

$0.965

$1.05

1-Week Range:

$0.96

$1.07

52-Week Range:

$0.90

$24.30

Jaguar Health Inc Stock (JAGX) Company Profile

Name

Jaguar Health Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

415-371-8300

Address

200 PINE STREET SUITE 400, SAN FRANCISCO, CA

Employee

Twitter

@Jaguar_Health

Next Earnings Date

2024-11-12

Latest SEC Filings

JAGX's Discussions on Twitter

Compare JAGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JAGX Jaguar Health Inc	0.9951	11.45M	10.72M	-39.71M	-32.21M	-15.55
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-07-21	Initiated	Cantor Fitzgerald	Overweight
Jul-11-17	Initiated	Rodman & Renshaw	Buy

Jaguar Health Inc Stock (JAGX) Latest News

Nov 25, 2024

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference - AccessWire

Nov 25, 2024

Jaguar Health CEO to Present at NobleCon20 and Emerging Growth Conference | JAGX Stock News - StockTitan

Nov 25, 2024

Nov 22, 2024

Jaguar Health seeking partner to develop, commercialize NP300 - TipRanks

Nov 22, 2024

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs - WSIL TV

Nov 22, 2024

Nov 19, 2024

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the YearEurope” - AccessWire

Nov 19, 2024

Napo Therapeutics Wins 'Best Pharma Innovator' Award, Advances Rare Disease Drug Trials | JAGX Stock News - StockTitan

Nov 19, 2024

Nov 16, 2024

Earnings call: Jaguar Health reports revenue growth in Q3 2024 By Investing.com - Investing.com Nigeria

Nov 16, 2024

Earnings call: Jaguar Health reports revenue growth in Q3 2024 - Investing.com

Nov 16, 2024

Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 16, 2024

Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Nov 16, 2024

Nov 14, 2024

Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024

Jaguar Health extends agreement with financial managers - Investing.com India

Nov 14, 2024